Ironwood cuts FY2022 revenue guidance to ~$411M; issues FY2023 outlook and files sNDA for pediatric LINZESS

IRONWOOD PHARMACEUTICALS INC

2022-FY EPS reported $0.96 revenue$410,596,000

Updated FY2022: total revenue ~$411M (prev. $420-430M), LINZESS net sales ~0% growth, adj. EBITDA ~$250M.
FY2023 guidance: revenue $420-435M, LINZESS net sales growth 3-5%, adj. EBITDA >$250M.
sNDA submitted to FDA for LINZESS in functional constipation in children 6-17; if approved, first FDA therapy for this population.
Expects ~$650M cash at YE2022; high single-digit LINZESS prescription demand growth in 2023.
Clinical milestone: CNP-104 data expected in H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRONWOOD PHARMACEUTICALS INC reported full year 2022 results: revenue ~$411 million. Guidance reaffirmed.

Period: full year 2022
Revenue: ~$411 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

expects: Previous 2022 Guidance (November 2022) Updated 2022 Guidance 1 LINZESS U.S. net sales growth 2 Low single digits % ~0% Total revenue $420 - $430 million ~$411 million Adjusted EBITDA 3 >$250 million ~$250 million Full Year 2023 Financial Guidance The table below summarizes Ironwood’s full year 2023 guidance. Ironwood expects: 2023 Guidance

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-002024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.